vs
通用动力（GD）与辉瑞（PFE）财务数据对比。点击上方公司名可切换其他公司
辉瑞的季度营收约是通用动力的1.2倍（$17.6B vs $14.4B），通用动力净利率更高（7.9% vs -9.4%，领先17.3%），通用动力同比增速更快（7.8% vs -1.2%），辉瑞自由现金流更多（$4.5B vs $952.0M），过去两年通用动力的营收复合增速更高（15.8% vs 8.6%）
通用动力是总部位于美国弗吉尼亚州雷斯顿的工业科技企业，是全球领先的先进军工装备研发生产商，产品覆盖核潜艇、主战坦克、装甲战车等多种品类，同时生产湾流系列公务机，也提供信息技术服务，位列美国前百名国防承包商第三位。
辉瑞是总部位于美国纽约曼哈顿The Spiral的跨国制药及生物技术企业，由德国企业家查尔斯·辉瑞与查尔斯·F·埃尔哈特于1849年在纽约创立，是北美地区历史最悠久的制药企业之一，在全球医药健康领域拥有较高的行业影响力。
GD vs PFE — 直观对比
营收规模更大
PFE
是对方的1.2倍
$14.4B
营收增速更快
GD
高出9.0%
-1.2%
净利率更高
GD
高出17.3%
-9.4%
自由现金流更多
PFE
多$3.6B
$952.0M
两年增速更快
GD
近两年复合增速
8.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.4B | $17.6B |
| 净利润 | $1.1B | $-1.6B |
| 毛利率 | — | 70.0% |
| 营业利润率 | 10.1% | -9.4% |
| 净利率 | 7.9% | -9.4% |
| 营收同比 | 7.8% | -1.2% |
| 净利润同比 | -0.4% | -501.7% |
| 每股收益（稀释后） | — | $-0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GDPFE
| Q4 25 | $14.4B | $17.6B | ||
| Q3 25 | $12.9B | $16.7B | ||
| Q2 25 | $13.0B | $14.7B | ||
| Q1 25 | $12.2B | $13.7B | ||
| Q4 24 | $13.3B | $17.8B | ||
| Q3 24 | $11.7B | $17.7B | ||
| Q2 24 | $12.0B | $13.3B | ||
| Q1 24 | $10.7B | $14.9B |
净利润GDPFE
| Q4 25 | $1.1B | $-1.6B | ||
| Q3 25 | $1.1B | $3.5B | ||
| Q2 25 | $1.0B | $2.9B | ||
| Q1 25 | $994.0M | $3.0B | ||
| Q4 24 | $1.1B | $410.0M | ||
| Q3 24 | $930.0M | $4.5B | ||
| Q2 24 | $905.0M | $41.0M | ||
| Q1 24 | $799.0M | $3.1B |
毛利率GDPFE
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 74.9% | ||
| Q2 25 | — | 74.2% | ||
| Q1 25 | — | 79.3% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | — | 70.3% | ||
| Q2 24 | — | 75.2% | ||
| Q1 24 | — | 77.3% |
营业利润率GDPFE
| Q4 25 | 10.1% | -9.4% | ||
| Q3 25 | 10.3% | 20.0% | ||
| Q2 25 | 10.0% | 20.8% | ||
| Q1 25 | 10.4% | 20.3% | ||
| Q4 24 | 10.7% | -0.1% | ||
| Q3 24 | 10.1% | 26.6% | ||
| Q2 24 | 9.7% | -0.8% | ||
| Q1 24 | 9.7% | 23.0% |
净利率GDPFE
| Q4 25 | 7.9% | -9.4% | ||
| Q3 25 | 8.2% | 21.3% | ||
| Q2 25 | 7.8% | 19.9% | ||
| Q1 25 | 8.1% | 21.6% | ||
| Q4 24 | 8.6% | 2.3% | ||
| Q3 24 | 8.0% | 25.2% | ||
| Q2 24 | 7.6% | 0.3% | ||
| Q1 24 | 7.4% | 20.9% |
每股收益（稀释后）GDPFE
| Q4 25 | — | $-0.29 | ||
| Q3 25 | — | $0.62 | ||
| Q2 25 | — | $0.51 | ||
| Q1 25 | — | $0.52 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | — | $0.78 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3B | $1.1B |
| 总债务越低越好 | $8.1B | — |
| 股东权益账面价值 | $25.6B | $86.5B |
| 总资产 | $57.2B | $208.2B |
| 负债/权益比越低杠杆越低 | 0.32× | — |
8季度趋势，按日历期对齐
现金及短期投资GDPFE
| Q4 25 | $2.3B | $1.1B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $1.5B | $1.6B | ||
| Q1 25 | $1.2B | $1.4B | ||
| Q4 24 | $1.7B | $1.0B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $1.4B | $1.1B | ||
| Q1 24 | $1.0B | $719.0M |
总债务GDPFE
| Q4 25 | $8.1B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GDPFE
| Q4 25 | $25.6B | $86.5B | ||
| Q3 25 | $24.4B | $92.8B | ||
| Q2 25 | $23.6B | $88.7B | ||
| Q1 25 | $22.2B | $90.3B | ||
| Q4 24 | $22.1B | $88.2B | ||
| Q3 24 | $23.0B | $92.3B | ||
| Q2 24 | $22.0B | $87.7B | ||
| Q1 24 | $21.4B | $92.3B |
总资产GDPFE
| Q4 25 | $57.2B | $208.2B | ||
| Q3 25 | $57.6B | $208.7B | ||
| Q2 25 | $56.9B | $206.1B | ||
| Q1 25 | $56.6B | $208.0B | ||
| Q4 24 | $55.9B | $213.4B | ||
| Q3 24 | $57.3B | $219.5B | ||
| Q2 24 | $55.4B | $216.2B | ||
| Q1 24 | $55.2B | $221.1B |
负债/权益比GDPFE
| Q4 25 | 0.32× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $5.3B |
| 自由现金流经营现金流 - 资本支出 | $952.0M | $4.5B |
| 自由现金流率自由现金流/营收 | 6.6% | 25.6% |
| 资本支出强度资本支出/营收 | 4.2% | 4.8% |
| 现金转化率经营现金流/净利润 | 1.37× | — |
| 过去12个月自由现金流最近4个季度 | $4.0B | $9.1B |
8季度趋势，按日历期对齐
经营现金流GDPFE
| Q4 25 | $1.6B | $5.3B | ||
| Q3 25 | $2.1B | $4.6B | ||
| Q2 25 | $1.6B | $-582.0M | ||
| Q1 25 | $-148.0M | $2.3B | ||
| Q4 24 | $2.2B | $6.7B | ||
| Q3 24 | $1.4B | $6.7B | ||
| Q2 24 | $814.0M | $-1.8B | ||
| Q1 24 | $-278.0M | $1.1B |
自由现金流GDPFE
| Q4 25 | $952.0M | $4.5B | ||
| Q3 25 | $1.9B | $4.0B | ||
| Q2 25 | $1.4B | $-1.2B | ||
| Q1 25 | $-290.0M | $1.8B | ||
| Q4 24 | $1.8B | $5.8B | ||
| Q3 24 | $1.2B | $6.1B | ||
| Q2 24 | $613.0M | $-2.4B | ||
| Q1 24 | $-437.0M | $386.0M |
自由现金流率GDPFE
| Q4 25 | 6.6% | 25.6% | ||
| Q3 25 | 14.7% | 24.0% | ||
| Q2 25 | 10.7% | -8.2% | ||
| Q1 25 | -2.4% | 12.9% | ||
| Q4 24 | 13.5% | 32.7% | ||
| Q3 24 | 10.4% | 34.3% | ||
| Q2 24 | 5.1% | -18.2% | ||
| Q1 24 | -4.1% | 2.6% |
资本支出强度GDPFE
| Q4 25 | 4.2% | 4.8% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 1.2% | 4.1% | ||
| Q4 24 | 2.7% | 5.2% | ||
| Q3 24 | 1.7% | 3.7% | ||
| Q2 24 | 1.7% | 4.8% | ||
| Q1 24 | 1.5% | 4.7% |
现金转化率GDPFE
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.99× | 1.30× | ||
| Q2 25 | 1.58× | -0.20× | ||
| Q1 25 | -0.15× | 0.79× | ||
| Q4 24 | 1.88× | 16.39× | ||
| Q3 24 | 1.52× | 1.50× | ||
| Q2 24 | 0.90× | -43.44× | ||
| Q1 24 | -0.35× | 0.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GD
| Aerospace | $3.8B | 26% |
| Cost Reimbursement | $2.5B | 17% |
| Information Technology Services | $2.1B | 15% |
| Militaryvehicles | $1.2B | 9% |
| C5ISR Solutions | $1.1B | 8% |
| Aircraft Services | $965.0M | 7% |
| Weapons Systemsand Munitions | $935.0M | 7% |
| Surfaceships | $920.0M | 6% |
| Engineeringand Other Services | $360.0M | 3% |
| Repairand Other Services | $344.0M | 2% |
| Contracts Accounted For Under Percentage Of Completion | $88.0M | 1% |
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
